URInary peptidomic patterns of Long-COVID syndrome
| Reference number | |
| Coordinator | Västra Götalandsregionen - Skaraborgs sjukhus Skövde |
| Funding from Vinnova | SEK 1 639 000 |
| Project duration | November 2022 - June 2025 |
| Status | Ongoing |
| Venture | European partnership for Personalised Medicine |
| Call | ERA PerMed Joint Transnational Call 2022: Personalised Prevention |
Purpose and goal
Individual risk prediction for the development of PASC at COVID onset and patient stratification to initiate personalized treatment for prevention of PASC.
Expected effects and result
Post acute sequelae of SARS-CoV-2 infection (PASC) [long COVID] is the most frequent, yet poorly characterized sequelae of COVID. The consortium published a first-in-class urinary peptidomic classifier (CoV-50) predicting the risk of severe COVID-19 course, enabling personalised patient management and intervention to save lives and reduce hospital costs. The successful molecular tools developed and used shall now be applied with the aim to predict PASC early after COVID-19 infection. This approach should allow personalised intervention to prevent/reduce PASC.
Planned approach and implementation
The study is based on molecular, clinical and demographic data from over 1000 COVID-19 patients collected during the European multicentre Crit-CoV-U study. The patients will be re-contacted to collect information on their health status, and PASC symptoms. Collaboration with patient advocacy group will provide strong links to patient´s viewpoints. Partners will incorporate proven expertise to approach patients and provide both clinical and molecular phenotyping. Data analysis will combine machine learning approaches with conventional multivariable analysis.